GlassScriptPhysician profile
Mandeep Singh Chandi
NPI 1225691165
$5,232.43
in general payments reported to CMS, 2019-2025
33 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $437 · 2024: $3,040 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307 · Travel and Lodging: $1,825 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,307.28 |
| Travel and Lodging | $1,825.16 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,633.44 | 2023-2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $387.80 | 2024-2025 | Breztri, Farxiga, Fasenra |
| Harmony Biosciences LLC | $338.09 | 2023-2025 | Wakix |
| Abbvie INC. | $229.62 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $218.18 | 2024-2025 | Mounjaro, Jardiance, Kisunla |
| Novo Nordisk INC | $198.44 | 2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $184.49 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.86 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $101.08 | 2024-2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $93.90 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.42 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $77.17 | 2024-2025 | |
| Stryker Corporation | $67.61 | 2025 | Blueprint Patient Specific Instrumentation |
| Merck Sharp & Dohme LLC | $53.05 | 2024-2025 | Lagevrio, Dificid, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $44.03 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.69 | 2025 | Krystexxa |
| Insmed, INC. | $34.28 | 2025 | Arikayce |
| Pfizer INC. | $32.24 | 2025 | |
| United Therapeutics Corporation | $31.59 | 2024 | Tyvaso, Remodulin, Orenitram |
| Almatica Pharma LLC | $31.00 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $29.05 | 2024-2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $28.82 | 2024 | Aralast |
| Philips North America LLC | $27.91 | 2023-2024 | (Ak6) Vest Therapy |
| Astellas Pharma US INC | $19.91 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $18.43 | 2025 | Gemtesa |
| Tolmar, INC. | $18.14 | 2025 | Jatenzo |
| Boston Scientific Corporation | $17.75 | 2025 | Wavewriter Alpha Prime 16 |
| Phadia US INC. | $17.04 | 2024 | Immunocap |
| Jazz Pharmaceuticals INC. | $15.88 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.15 | 2025 | |
| Antares Pharma, INC. | $15.15 | 2025 | Xyosted |
| Acella Pharmaceuticals, LLC | $13.85 | 2025 | NP Thyroid 60 |
| Xeris Pharmaceuticals, INC. | $13.37 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Chandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.